Your session is about to expire
← Back to Search
Iodine-131 Anti-B1 Antibody for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing a new cancer treatment that uses Iodine-131 Anti-B1 Antibody to target and kill cancer cells. The study will help doctors determine the best dose of the treatment and if it is safe and effective for patients with NHL who have cancer in their bone marrow.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Find a Location
Who is running the clinical trial?
Media Library
- My initial diagnosis was low-grade non-Hodgkin's B-cell lymphoma or de novo follicular large cell lymphoma.My cancer did not respond or got worse after my last chemotherapy.I do not have severe heart disease or other serious illnesses that would interfere with the study.I've been cancer-free for 5 years, except for skin cancer, in situ cervical cancer, or lymphoma.I have had a stem cell or bone marrow transplant.I haven't had chemotherapy, immunosuppressants, or cytokine therapy in the last 4 weeks.My cancer got worse within a year after receiving high-dose radiation.I am currently taking medication for cancer.I have a certain type of aggressive non-Hodgkin lymphoma, but not the intermediate follicular large cell type.My lymphoma is advanced (stage IV) with significant bone marrow involvement.My kidney and liver functions are within normal ranges.I can care for myself and expect to live at least 3 more months.I have had radioimmunotherapy before.My tumor tests positive for the CD20 protein.I have a tumor that is at least 2 x 2 cm large.I have a kidney blockage causing swelling.My cancer has spread to my brain or its coverings.I do not have an active infection needing IV drugs.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment into this research endeavor still open?
"As per clinicaltrials.gov, this medical trial is not enrolling any more patients at present. The experiment was initially posted on May 1st 1999 and most recently edited on June 23rd 2005. Although recruitment for the study has ceased, there are 1779 other studies that still require participants to take part in them."
To whom is enrollment in this clinical investigation available?
"This clinical trial is seeking 24 candidates who have been diagnosed with lymphoma and are aged 18 or older. In order to qualify, participants must possess a minimum performance status of 60% on the Karnofsky Performance Scale, an expected survival time frame of 3 months or greater, bi-dimensionally measurable disease (with at least one lesion being 2 x 2 cm in size), Ann Arbor Stage IV illness that has seen 25% or more involvement by NHL within the intratrabecular marrow space as observed via dual bone marrow biopsy specimens upon study entrance; alternatively a single biopsy can be done if it highlights over 50% involvement"
Does this experiment accommodate participants older than 35 years?
"This medical study is enrolling participants aged 18 and older."
What precautions should be taken in order to guarantee the security of those undergoing this therapy?
"Considering the lack of data on efficacy and safety, our assessment team at Power gave this treatment a score of 1."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger